The Journal of Allergy and Clinical Immunology: In Practice
Clinical CommunicationsMepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature
References (10)
- et al.
Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature
Respir Med
(2017) - et al.
Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)
Respir Med
(2014) Clinical aspects of allergic bronchopulmonary aspergillosis
Front Biosci
(2003)- et al.
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
N Engl J Med
(2000) - et al.
Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA?
Eur Respir J
(2008)
Cited by (26)
Corticosteroid-sparing effect of biologics in patients with allergic bronchopulmonary aspergillosis
2024, Annals of Allergy, Asthma and ImmunologyBiologics for severe asthma and beyond
2023, Pharmacology and TherapeuticsAllergic bronchopulmonary aspergillosis: A multidisciplinary review
2023, Journal of Medical MycologyComorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma
2023, Journal of Allergy and Clinical Immunology: In PracticeMepolizumab in allergic bronchopulmonary aspergillosis complicated by infection
2023, Respiratory Medicine Case ReportsTreatments of refractory eosinophilic lung diseases with biologics
2023, Allergology InternationalCitation Excerpt :The expected effects of biologics on ABPA patients are as follows: reducing the ABPA exacerbation rate, improving clinical symptoms (including uncontrolled asthma) and radiographic findings, reducing the maintenance dose of OCS, and treating patients unable to receive standard treatment. Case reports, case series, small RCTs have demonstrated the efficacy and safety of omalizumab,44–49 mepolizumab,50–57 benralizumab,58–60 and dupilumab.61–65 Table 3 demonstrates case series studies including 5 or more cases of ABPA/ABPM treated with biologics.
The BSAR website is supported by unrestricted grants from Novartis, GSK, Chiesi, Boehringer, Astrazeneca, Teva and Sanofi.
Conflicts of interest: The authors declare that they have no relevant conflicts of interest.